Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Debt (2024 - 2025)

Historic Non-Current Debt for Apellis Pharmaceuticals (APLS) over the last 2 years, with Q3 2025 value amounting to $361.1 million.

  • Apellis Pharmaceuticals' Non-Current Debt rose 58.75% to $361.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $361.1 million, marking a year-over-year increase of 58.75%. This contributed to the annual value of $359.5 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Non-Current Debt stood at $361.1 million, which was up 58.75% from $360.5 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Non-Current Debt's 5-year high stood at $364.0 million during Q2 2024, with a 5-year trough of $359.0 million in Q3 2024.